interim marketing authorization regarding the use of alpha-amylase used in starch used in the production of dextrins maltose dextrose glucose glucose syrup or glucose solids dried glucose syrup and in distillers mash brewers mash bread flour whole wheat flour and unstandardized bakery products health canada has received a submission to permit the use of the alpha-amylase derived from a genetically modified bacillus licheniformis bacillus licheniformis strain 3266 plcath-3266ori1 that carries the gene from bacillus stearothermophilus coding for this enzyme. this alpha-amylase will be used in starch used in the production of dextrins maltose dextrose glucose glucose syrup or glucose solids dried glucose syrup and in distillers mash brewers mash bread flour whole wheat flour and unstandardized bakery products at levels consistent with good manufacturing practice. evaluation of available data supports the safety and effectiveness of the alpha-amylase derived from bacillus licheniformis strain 3266 plcath-3266ori1 in these food products. therefore it is the intention of health canada to recommend that the food and drug regulations be amended to permit the use of the alpha-amylase derived from bacillus licheniformis strain 3266 plcath-3266ori1 in the production of the foods listed above at levels consistent with good manufacturing practice. as a means to improve the responsiveness of the regulatory system an interim marketing authorization ima is being issued to permit the immediate use of the alpha-amylase derived from bacillus licheniformis strain 3266 plcath-3266ori1 in the production of the foods listed above at levels consistent with good manufacturing practice while the regulatory process is undertaken to formally amend the regulations. the proposed regulatory amendments would be enabling measures to allow the sale of the foods mentioned above that have been manufactured through the use of the alpha-amylase derived from bacillus licheniformis strain 3266 plcath-3266ori1 .